Insights On CONTRACT PHARMA MANUFACTURING

  1. The Science Of Collaboration: Building Smarter Cell Therapy Partnership 1/20/2026

    Successful cell therapy programs rely on evolving, science‑driven partnerships that integrate CMC strategy, deepen rigor over time, and translate complex research into scalable, compliant, clinically ready processes.

  2. Built‑In Quality For Audit‑Ready Manufacturing 1/20/2026

    Pre‑approval inspection readiness requires embedding quality, traceability, contamination control, and robust analytical and documentation practices into everyday cell therapy manufacturing to prevent delays and ensure regulatory confidence.

  3. Balancing Speed And Regulation In Cell Therapy 1/20/2026

    Rapid cell therapy development demands early planning for scalability, standardized platforms, and inspection‑ready operations to meet rising regulatory expectations and avoid costly rework in later clinical phases.

  4. Designing Cell Therapy Analytical Programs For Regulatory Success 1/20/2026

    Expedited cell therapy pathways demand early, reliable analytical development to ensure robust data, regulatory confidence, and smooth transitions from discovery through clinical stages without costly delays.

  5. What To Expect From A Sterile Injectables CDMO 1/20/2026

    Sterile injectable manufacturing demands built‑in contamination control, rigorous monitoring, skilled personnel, and robust quality systems, far beyond sterility testing, to ensure safety, compliance, and reliable CDMO performance.

  6. Closing And Following Up After A CDMO Audit 1/20/2026

    Closing and following up after a CDMO audit requires organized findings, clear communication, actionable recommendations, and ongoing collaboration to strengthen compliance, drive improvements, and build long‑term partnership success.

  7. New Standards For Elastomeric Components In Sterile Packaging 1/20/2026

    USP’s new elastomeric packaging standards shift testing to full system‑level evaluation, strengthen integrity and usability expectations, and place compliance responsibility on drug developers.

  8. Modern Lentiviral Platforms For Scalable Cell Therapy 1/20/2026

    A new platform approach streamlines lentiviral vector design and manufacturing, boosting yield, lowering costs, and accelerating access to gene‑modified cell therapies worldwide.

  9. Sterile Injectables: Why Innovation Matters More Than Ever 1/15/2026

    New technologies and regulatory changes are shaping safer, more efficient filling processes. Discover why innovation is key to protecting patients and advancing therapies.

  10. Mastering Ophthalmic Drug Formulation And Testing 1/15/2026

    In this on-demand webinar, our manufacturing experts provide insights into the growing ophthalmic market and how to optimize your drug development research outcomes.